SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

Beam Therapeutics Posts Narrower Q4 Loss, But Misses Estimates; Has Enough Capital Through At Least 2022, Says Wedbush

· 03/15/2021 13:46

Please log in to view news